Example of Molecular Cancer format
Recent searches

Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format Example of Molecular Cancer format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access
recommended Recommended

Molecular Cancer — Template for authors

Publisher: Springer
Categories Rank Trend in last 3 yrs
Molecular Medicine #2 of 167 up up by 5 ranks
Cancer Research #5 of 207 up up by 10 ranks
Oncology #8 of 340 up up by 12 ranks
journal-quality-icon Journal quality:
High
calendar-icon Last 4 years overview: 637 Published Papers | 21863 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 16/07/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access
recommended Recommended

Springer

Quality:  
High
CiteRatio: 10.4
SJR: 5.06
SNIP: 2.281
open access Open Access
recommended Recommended

Nature

Quality:  
High
CiteRatio: 16.0
SJR: 4.539
SNIP: 2.28
open access Open Access
recommended Recommended

American Association for Cancer Research

Quality:  
High
CiteRatio: 15.8
SJR: 4.103
SNIP: 1.983
open access Open Access
recommended Recommended

American Association for Cancer Research

Quality:  
High
CiteRatio: 18.2
SJR: 5.427
SNIP: 2.243

Journal Performance & Insights

Impact Factor

CiteRatio

Determines the importance of a journal by taking a measure of frequency with which the average article in a journal has been cited in a particular year.

A measure of average citations received per peer-reviewed paper published in the journal.

15.302

43% from 2018

Impact factor for Molecular Cancer from 2016 - 2019
Year Value
2019 15.302
2018 10.679
2017 7.776
2016 6.204
graph view Graph view
table view Table view

34.3

81% from 2019

CiteRatio for Molecular Cancer from 2016 - 2020
Year Value
2020 34.3
2019 19.0
2018 14.9
2017 13.5
2016 11.7
graph view Graph view
table view Table view

insights Insights

  • Impact factor of this journal has increased by 43% in last year.
  • This journal’s impact factor is in the top 10 percentile category.

insights Insights

  • CiteRatio of this journal has increased by 81% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

7.274

59% from 2019

SJR for Molecular Cancer from 2016 - 2020
Year Value
2020 7.274
2019 4.581
2018 3.274
2017 2.778
2016 2.439
graph view Graph view
table view Table view

4.213

42% from 2019

SNIP for Molecular Cancer from 2016 - 2020
Year Value
2020 4.213
2019 2.969
2018 2.006
2017 1.707
2016 1.517
graph view Graph view
table view Table view

insights Insights

  • SJR of this journal has increased by 59% in last years.
  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has increased by 42% in last years.
  • This journal’s SNIP is in the top 10 percentile category.

Molecular Cancer

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

Springer

Molecular Cancer

Approved by publishing and review experts on SciSpace, this template is built as per for Molecular Cancer formatting guidelines as mentioned in Springer author instructions. The current version was created on and has been used by 982 authors to write and format their manuscripts to this journal.

i
Last updated on
16 Jul 2020
i
ISSN
1606-8610
i
Open Access
Yes
i
Sherpa RoMEO Archiving Policy
White faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Citation Type
Numbered
[25]
i
Bibliography Example
Blonder, G.E., Tinkham, M., Klapwijk, T.M.: Transition from metallic to tunneling regimes in superconducting microconstrictions: Excess current, charge imbalance, and supercurrent conversion. Phys. Rev. B 25(7), 4515–4532 (1982)

Top papers written in this journal

open accessOpen access Journal Article DOI: 10.1186/1476-4598-12-86
The complexity of NF-κB signaling in inflammation and cancer
Bastian Hoesel, Johannes A. Schmid1
02 Aug 2013 - Molecular Cancer

Abstract:

The NF-κB family of transcription factors has an essential role in inflammation and innate immunity. Furthermore, NF-κB is increasingly recognized as a crucial player in many steps of cancer initiation and progression. During these latter processes NF-κB cooperates with multiple other signaling molecules and pathways. Promine... The NF-κB family of transcription factors has an essential role in inflammation and innate immunity. Furthermore, NF-κB is increasingly recognized as a crucial player in many steps of cancer initiation and progression. During these latter processes NF-κB cooperates with multiple other signaling molecules and pathways. Prominent nodes of crosstalk are mediated by other transcription factors such as STAT3 and p53 or the ETS related gene ERG. These transcription factors either directly interact with NF-κB subunits or affect NF-κB target genes. Crosstalk can also occur through different kinases, such as GSK3-β, p38, or PI3K, which modulate NF-κB transcriptional activity or affect upstream signaling pathways. Other classes of molecules that act as nodes of crosstalk are reactive oxygen species and miRNAs. In this review, we provide an overview of the most relevant modes of crosstalk and cooperativity between NF-κB and other signaling molecules during inflammation and cancer. read more read less

Topics:

Crosstalk (biology) (64%)64% related to the paper, Transcription factor (54%)54% related to the paper, Cell signaling (53%)53% related to the paper, STAT3 (51%)51% related to the paper, Signal transduction (51%)51% related to the paper
View PDF
2,404 Citations
open accessOpen access Journal Article DOI: 10.1186/1476-4598-5-67
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.
02 Dec 2006 - Molecular Cancer

Abstract:

Recently, a small population of cancer stem cells in adult and pediatric brain tumors has been identified. Some evidence has suggested that CD133 is a marker for a subset of leukemia and glioblastoma cancer stem cells. Especially, CD133 positive cells isolated from human glioblastoma may initiate tumors and represent novel ta... Recently, a small population of cancer stem cells in adult and pediatric brain tumors has been identified. Some evidence has suggested that CD133 is a marker for a subset of leukemia and glioblastoma cancer stem cells. Especially, CD133 positive cells isolated from human glioblastoma may initiate tumors and represent novel targets for therapeutics. The gene expression and the drug resistance property of CD133 positive cancer stem cells, however, are still unknown. In this study, by FACS analysis we determined the percentage of CD133 positive cells in three primary cultured cell lines established from glioblastoma patients 10.2%, 69.7% and 27.5%, respectively. We also determined the average mRNA levels of markers associated with neural precursors. For example, CD90, CD44, CXCR4, Nestin, Msi1 and MELK mRNA on CD133 positive cells increased to 15.6, 5.7, 337.8, 21.4, 84 and 1351 times, respectively, compared to autologous CD133 negative cells derived from cell line No. 66. Additionally, CD133 positive cells express higher levels of BCRP1 and MGMT mRNA, as well as higher mRNA levels of genes that inhibit apoptosis. Furthermore, CD133 positive cells were significantly resistant to chemotherapeutic agents including temozolomide, carboplatin, paclitaxel (Taxol) and etoposide (VP16) compared to autologous CD133 negative cells. Finally, CD133 expression was significantly higher in recurrent GBM tissue obtained from five patients as compared to their respective newly diagnosed tumors. Our study for the first time provided evidence that CD133 positive cancer stem cells display strong capability on tumor's resistance to chemotherapy. This resistance is probably contributed by the CD133 positive cell with higher expression of on BCRP1 and MGMT, as well as the anti-apoptosis protein and inhibitors of apoptosis protein families. Future treatment should target this small population of CD133 positive cancer stem cells in tumors to improve the survival of brain tumor patients. read more read less

Topics:

Cancer stem cell (68%)68% related to the paper, CD90 (61%)61% related to the paper, CD44 (58%)58% related to the paper, CXCR4 (56%)56% related to the paper, Temozolomide (56%)56% related to the paper
View PDF
1,725 Citations
open accessOpen access Journal Article DOI: 10.1186/1476-4598-10-38
The functional role of long non-coding RNA in human carcinomas
Ewan A. Gibb, Carolyn J. Brown1, Wan L. Lam1
13 Apr 2011 - Molecular Cancer

Abstract:

Long non-coding RNAs (lncRNAs) are emerging as new players in the cancer paradigm demonstrating potential roles in both oncogenic and tumor suppressive pathways. These novel genes are frequently aberrantly expressed in a variety of human cancers, however the biological functions of the vast majority remain unknown. Recently, ... Long non-coding RNAs (lncRNAs) are emerging as new players in the cancer paradigm demonstrating potential roles in both oncogenic and tumor suppressive pathways. These novel genes are frequently aberrantly expressed in a variety of human cancers, however the biological functions of the vast majority remain unknown. Recently, evidence has begun to accumulate describing the molecular mechanisms by which these RNA species function, providing insight into the functional roles they may play in tumorigenesis. In this review, we highlight the emerging functional role of lncRNAs in human cancer. read more read less

Topics:

Long non-coding RNA (54%)54% related to the paper
View PDF
1,464 Citations
open accessOpen access Journal Article DOI: 10.1186/S12943-017-0663-2
CircRNA: functions and properties of a novel potential biomarker for cancer
23 May 2017 - Molecular Cancer

Abstract:

Circular RNAs, a novel class of endogenous noncoding RNAs, are characterized by their covalently closed loop structures without a 5′ cap or a 3′ Poly A tail. Although the mechanisms of circular RNAs’ generation and function are not fully clear, recent research has shown that circular RNAs may function as potential molecular m... Circular RNAs, a novel class of endogenous noncoding RNAs, are characterized by their covalently closed loop structures without a 5′ cap or a 3′ Poly A tail. Although the mechanisms of circular RNAs’ generation and function are not fully clear, recent research has shown that circular RNAs may function as potential molecular markers for disease diagnosis and treatment and play an important role in the initiation and progression of human diseases, especially in tumours. This review summarizes some information about categories, biogenesis, functions at the molecular level, properties of circular RNAs and the possibility of circular RNAs as biomarkers in cancers. read more read less

Topics:

Non-coding RNA (54%)54% related to the paper, microRNA (51%)51% related to the paper, RNA (51%)51% related to the paper
View PDF
1,072 Citations
open accessOpen access Journal Article DOI: 10.1186/1476-4598-5-29
Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues
19 Jul 2006 - Molecular Cancer

Abstract:

MicroRNAs (miRNAs) are short non-coding RNA molecules playing regulatory roles by repressing translation or cleaving RNA transcripts. Although the number of verified human miRNA is still expanding, only few have been functionally described. However, emerging evidences suggest the potential involvement of altered regulation of... MicroRNAs (miRNAs) are short non-coding RNA molecules playing regulatory roles by repressing translation or cleaving RNA transcripts. Although the number of verified human miRNA is still expanding, only few have been functionally described. However, emerging evidences suggest the potential involvement of altered regulation of miRNA in pathogenesis of cancers and these genes are thought to function as both tumours suppressor and oncogenes. In our study, we examined by Real-Time PCR the expression of 156 mature miRNA in colorectal cancer. The analysis by several bioinformatics algorithms of colorectal tumours and adjacent non-neoplastic tissues from patients and colorectal cancer cell lines allowed identifying a group of 13 miRNA whose expression is significantly altered in this tumor. The most significantly deregulated miRNA being miR-31, miR-96, miR-133b, miR-135b, miR-145, and miR-183. In addition, the expression level of miR-31 was correlated with the stage of CRC tumor. Our results suggest that miRNA expression profile could have relevance to the biological and clinical behavior of colorectal neoplasia. read more read less

Topics:

Gene silencing (61%)61% related to the paper, mir-31 (59%)59% related to the paper, microRNA (55%)55% related to the paper, Gene expression profiling (50%)50% related to the paper
View PDF
910 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for Molecular Cancer.

It automatically formats your research paper to Springer formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write Molecular Cancer in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the Molecular Cancer guidelines and auto format it.

2. Do you follow the Molecular Cancer guidelines?

Yes, the template is compliant with the Molecular Cancer guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in Molecular Cancer?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the Molecular Cancer citation style.

4. Can I use the Molecular Cancer templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for Molecular Cancer.

5. Can I use a manuscript in Molecular Cancer that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper Molecular Cancer that you can download at the end.

6. How long does it usually take you to format my papers in Molecular Cancer?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in Molecular Cancer.

7. Where can I find the template for the Molecular Cancer?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Molecular Cancer's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the Molecular Cancer's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. Molecular Cancer an online tool or is there a desktop version?

SciSpace's Molecular Cancer is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like Molecular Cancer?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like Molecular Cancer?”

11. What is the output that I would get after using Molecular Cancer?

After writing your paper autoformatting in Molecular Cancer, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is Molecular Cancer's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for Molecular Cancer?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for Molecular Cancer. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In Molecular Cancer?

The 5 most common citation types in order of usage for Molecular Cancer are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the Molecular Cancer?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Molecular Cancer's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download Molecular Cancer in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in Molecular Cancer Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to Molecular Cancer formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template